Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	Oliena Studio Stroke and language recovery: 9000+ videos Español • Italiano • Sardu • English | PDF+

Lung Cancer

Free Subscription 13.01.2020 1 Am J Clin Oncol 1 Am J Respir Crit Care Med 2 Ann Oncol 4 Ann Thorac Surg 7 Anticancer Res 1 Arch Bronconeumol 1 Arch Pathol Lab Med 6 BMC Cancer 1 Cancer Lett 3 Cancer Res 1 Chest 1 Clin Cancer Res 1 Clin Lung Cancer 2 Eur J Cardiothorac Surg 1 Eur Respir J 3 Int J Oncol 4 Int J Radiat Oncol Biol Phys 1 J Cancer Res Clin Oncol 2 J Clin Oncol 6 J Thorac Oncol 15 Lung Cancer 1 Lung Cancer (Auckl) 1 Oncogene 5 Oncol Rep 2 PLoS One

Retrieve available abstracts of this week’s articles: HTML format Text format

Single Articles

Am J Clin Oncol

1. WONG JK, Shaikh T, DeMora L, Zhang E, et al
   Predictors of Distant Recurrence Following Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer.
   Am J Clin Oncol. 2020 Jan 7. doi: 10.1097/COC.0000000000000662.
   PubMed     Text format     Abstract available
   
   

   
   Am J Respir Crit Care Med

2. BURNETT-HARTMAN AN, Wiener RS
   Lessons Learned to Promote Lung Cancer Screening and Pre-Empt Worsening Lung Cancer Disparities.
   Am J Respir Crit Care Med. 2020 Jan 6. doi: 10.1164/rccm.201912-2398.
   PubMed     Text format    
   
   

   
   Ann Oncol

3. DE RUYSSCHER D, Faivre-Finn C, Nackaerts K, Jordan K, et al
   Recommendation for supportive care in patients receiving concurrent chemotherapy and radiotherapy for lung cancer.
   Ann Oncol. 2020;31:41-49.
   PubMed     Text format     Abstract available
   
   
4. HAZELL SZ, Fu W, Hu C, Voong KR, et al
   Financial toxicity in lung cancer: an assessment of magnitude, perception, and impact on quality of life.
   Ann Oncol. 2020;31:96-102.
   PubMed     Text format     Abstract available
   
   

   
   Ann Thorac Surg

5. KINOSHITA T, Ujiie H, Chen J, Ding L, et al
   Evaluation of novel imaging devices for nanoparticle-mediated fluorescence-guided lung tumor therapy.
   Ann Thorac Surg. 2019 Feb 8. pii: S0003-4975(19)30184.
   PubMed     Text format     Abstract available
   
   
6. HUNG WT, Hung MH, Wang ML, Cheng YJ, et al
   Nonintubated Thoracoscopic Surgery for Lung Tumor: Seven Years' Experience With 1,025 Patients.
   Ann Thorac Surg. 2019;107:1607-1612.
   PubMed     Text format     Abstract available
   
   
7. NARDONE V, Correale P, Guida C
   The Optimal Choice of Local Therapy for Stage IIIA-N2 NSCLC: Is Radiotherapy Inferior to Surgery?
   Ann Thorac Surg. 2019;108:961-962.
   PubMed     Text format    
   
   
8. ZHAO Y, Liang W, He J
   Reply.
   Ann Thorac Surg. 2019;108:962-963.
   PubMed     Text format    
   
   

   
   Anticancer Res

9. KAIRA K, Shimizu K, Endoh H, Imaizumi K, et al
   Prognostic Significance of Tumor Immunity in Surgically Resected Pulmonary Pleomorphic Carcinoma.
   Anticancer Res. 2020;40:261-269.
   PubMed     Text format     Abstract available
   
   
10. MIN HY, Jung Y, Park KH, Lee HY, et al
    Papuamine Inhibits Viability of Non-small Cell Lung Cancer Cells by Inducing Mitochondrial Dysfunction.
    Anticancer Res. 2020;40:323-333.
    PubMed     Text format     Abstract available
    
    
11. ANZAI M, Yamamoto N, Hayashi K, Nakajima M, et al
    Safety and Efficacy of Carbon-ion Radiotherapy Alone for Stage III Non-small Cell Lung Cancer.
    Anticancer Res. 2020;40:379-386.
    PubMed     Text format     Abstract available
    
    
12. NIIBE Y, Yamamoto T, Onishi H, Yamashita H, et al
    Pulmonary Oligometastases Treated by Stereotactic Body Radiation Therapy: A Nationwide Survey of 1,378 Patients.
    Anticancer Res. 2020;40:393-399.
    PubMed     Text format     Abstract available
    
    
13. OKAUCHI S, Watanabe H, Yamada H, Sato S, et al
    The Prognosis of Lung Cancer With Different Metastatic Patterns.
    Anticancer Res. 2020;40:421-426.
    PubMed     Text format     Abstract available
    
    
14. GIANONCELLI L, Spitaleri G, Passaro A, Radice D, et al
    Efficacy of Anti-PD1/PD-L1 Therapy (IO) in KRAS Mutant Non-small Cell Lung Cancer Patients: A Retrospective Analysis.
    Anticancer Res. 2020;40:427-433.
    PubMed     Text format     Abstract available
    
    
15. WATANABE H, Okauchi S, Yamada H, Sato S, et al
    Application of Cluster Analysis to Distant Metastases from Lung Cancer.
    Anticancer Res. 2020;40:413-419.
    PubMed     Text format     Abstract available
    
    

    
    Arch Bronconeumol

16. GOROSPE L, Pacios-Blanco RE, Garrido-Lopez P
    The Importance of Imaging Studies in the Assessment of Response to Immunotherapy in Lung Cancer.
    Arch Bronconeumol. 2019 Dec 30. pii: S0300-2896(19)30580.
    PubMed     Text format     Abstract available
    
    

    
    Arch Pathol Lab Med

17. NIZAMADDIN SK, Mehrotra M, Nadhim ASH, Luthra R, et al
    Detection of EGFR T790M Mutation by Droplet Digital Polymerase Chain Reaction in Lung Carcinoma Cytology Samples.
    Arch Pathol Lab Med. 2020 Jan 6. doi: 10.5858/arpa.2019-0411.
    PubMed     Text format     Abstract available
    
    

    
    BMC Cancer

18. DJUREINOVIC D, Ponten V, Landelius P, Al Sayegh S, et al
    Multiplex plasma protein profiling identifies novel markers to discriminate patients with adenocarcinoma of the lung.
    BMC Cancer. 2019;19:741.
    PubMed     Text format     Abstract available
    
    
19. XU S, Wang W, Xu C, Li X, et al
    ROS1-ADGRG6: a case report of a novel ROS1 oncogenic fusion variant in lung adenocarcinoma and the response to crizotinib.
    BMC Cancer. 2019;19:769.
    PubMed     Text format     Abstract available
    
    
20. CHEN Y, Wei J, Cai J, Liu A, et al
    Combination therapy of brain radiotherapy and EGFR-TKIs is more effective than TKIs alone for EGFR-mutant lung adenocarcinoma patients with asymptomatic brain metastasis.
    BMC Cancer. 2019;19:793.
    PubMed     Text format     Abstract available
    
    
21. KIM KH, Chung C, Kim JM, Lee D, et al
    Clinical significance of atypical protein kinase C (PKCiota and PKCzeta) and its relationship with yes-associated protein in lung adenocarcinoma.
    BMC Cancer. 2019;19:804.
    PubMed     Text format     Abstract available
    
    
22. HARLE A, Molassiotis A, Buffin O, Burnham J, et al
    A cross sectional study to determine the prevalence of cough and its impact in patients with lung cancer: a patient unmet need.
    BMC Cancer. 2020;20:9.
    PubMed     Text format     Abstract available
    
    
23. CHEN Z, Teng X, Zhang J, Huang K, et al
    Molecular features of lung adenocarcinoma in young patients.
    BMC Cancer. 2019;19:777.
    PubMed     Text format     Abstract available
    
    

    
    Cancer Lett

24. ZHOU Z, Zhou Q, Wu X, Xu S, et al
    VCAM-1 secreted from cancer-associated fibroblasts enhances the growth and invasion of lung cancer cells through AKT and MAPK signaling.
    Cancer Lett. 2020;473:62-73.
    PubMed     Text format     Abstract available
    
    

    
    Cancer Res

25. RAMAMOORTHY P, Thomas SM, Kaushik G, Subramaniam D, et al
    Metastatic Tumor-in-a-Dish, a Novel Multicellular Organoid to Study Lung Colonization and Predict Therapeutic Response.
    Cancer Res. 2019;79:1681-1695.
    PubMed     Text format     Abstract available
    
    
26. WANG S, Rong R, Yang DM, Fujimoto J, et al
    Computational staining of pathology images to study the tumor microenvironment in lung cancer.
    Cancer Res. 2020 Jan 8. pii: 0008-5472.CAN-19-1629.
    PubMed     Text format     Abstract available
    
    
27. VUONG L, Kouverianou E, Rooney CM, McHugh BJ, et al
    An Orally Active Galectin-3 Antagonist Inhibits Lung Adenocarcinoma Growth and Augments Response to PD-L1 Blockade.
    Cancer Res. 2019;79:1480-1492.
    PubMed     Text format     Abstract available
    
    

    
    Chest

28. YONG PC, Sigel K, Rehmani S, Wisnivesky J, et al
    Lung Cancer Screening Uptake in the United States.
    Chest. 2020;157:236-238.
    PubMed     Text format    
    
    

    
    Clin Cancer Res

29. SCHOENFELD AJ, Chan JM, Kubota D, Sato H, et al
    Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer.
    Clin Cancer Res. 2020 Jan 7. pii: 1078-0432.CCR-19-3563.
    PubMed     Text format     Abstract available
    
    

    
    Clin Lung Cancer

30. STEFFEN MCLOUTH LE, Lycan TW Jr, Levine BJ, Gabbard J, et al
    Patient-Reported Outcomes From Patients Receiving Immunotherapy or Chemoimmunotherapy for Metastatic Non-Small-Cell Lung Cancer in Clinical Practice.
    Clin Lung Cancer. 2019 Nov 29. pii: S1525-7304(19)30332.
    PubMed     Text format     Abstract available
    
    

    
    Eur J Cardiothorac Surg

31. INCI I, Benker M, Citak N, Schneiter D, et al
    Complex sleeve lobectomy has the same surgical outcome when compared with conventional lobectomy in patients with lung cancer.
    Eur J Cardiothorac Surg. 2020 Jan 9. pii: 5699252. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
32. WINCKELMANS T, Decaluwe H, De Leyn P, Van Raemdonck D, et al
    Segmentectomy or lobectomy for early-stage non-small-cell lung cancer: a systematic review and meta-analysis.
    Eur J Cardiothorac Surg. 2020 Jan 3. pii: 5695530. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    

    
    Eur Respir J

33. HENDRIKS LEL, Cadranel J, Berghmans T
    Current challenges in the management of nonsmall cell lung cancer brain metastases.
    Eur Respir J. 2020;55.
    PubMed     Text format    
    
    

    
    Int J Oncol

34. REN T, Fan XX, Wang MF, Duan FG, et al
    miR20b promotes growth of nonsmall cell lung cancer through a positive feedback loop of the Wnt/betacatenin signaling pathway.
    Int J Oncol. 2019 Dec 13. doi: 10.3892/ijo.2019.4940.
    PubMed     Text format     Abstract available
    
    
35. DING Z, Du W, Lei Z, Zhang Y, et al
    Neuropilin 1 modulates TGFbeta1induced epithelialmesenchymal transition in nonsmall cell lung cancer.
    Int J Oncol. 2019 Dec 11. doi: 10.3892/ijo.2019.4938.
    PubMed     Text format     Abstract available
    
    
36. PARK S, Lim JM, Chun JN, Lee S, et al
    Altered expression of fucosylation pathway genes is associated with poor prognosis and tumor metastasis in nonsmall cell lung cancer.
    Int J Oncol. 2019 Dec 24. doi: 10.3892/ijo.2019.4953.
    PubMed     Text format     Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

37. OZSAHIN M, Slotman BJ, Bourhis J
    Reproductive Viability of Cells Following Preoperative Stereotactic Ablative Radiotherapy.
    Int J Radiat Oncol Biol Phys. 2019;105:233-234.
    PubMed     Text format    
    
    
38. YOUNG MR, Decker RH
    SBRT for Early Stage Laryngeal Cancer: Progress, But Not Quite Ready for Prime Time.
    Int J Radiat Oncol Biol Phys. 2019;105:121-123.
    PubMed     Text format    
    
    
39. HOPPE RT
    20 Gy Versus 30 Gy: Will it Make a Difference?
    Int J Radiat Oncol Biol Phys. 2019;105:102-103.
    PubMed     Text format    
    
    
40. BILLFALK-KELLY A, Yu E, Su J, O'Sullivan B, et al
    Radiologic Extranodal Extension Portends Worse Outcome in cN+ TNM-8 Stage I Human Papillomavirus-Mediated Oropharyngeal Cancer.
    Int J Radiat Oncol Biol Phys. 2019;104:1017-1027.
    PubMed     Text format     Abstract available
    
    

    
    J Cancer Res Clin Oncol

41. TIAN P, Liu Y, Zeng H, Tang Y, et al
    Unique molecular features and clinical outcomes in young patients with non-small cell lung cancer harboring ALK fusion genes.
    J Cancer Res Clin Oncol. 2020 Jan 1. pii: 10.1007/s00432-019-03116.
    PubMed     Text format     Abstract available
    
    

    
    J Clin Oncol

42. TANAKA T, Ishiki H, Kubo E, Yokota S, et al
    Is Gefitinib Combined With Platinum-Doublet Chemotherapy a Counterpart to Osimertinib Monotherapy in Advanced EGFR-Mutated Non-Small-Cell Lung Cancer in the First-Line Setting?
    J Clin Oncol. 2020 Jan 2:JCO1902509. doi: 10.1200/JCO.19.02509.
    PubMed     Text format    
    
    
43. XIE L, Fan X, Qian B
    Maintenance Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer: More Questions Than Answers.
    J Clin Oncol. 2020 Jan 2:JCO1902356. doi: 10.1200/JCO.19.02356.
    PubMed     Text format    
    
    

    
    J Thorac Oncol

44. DAVIES KD, Villalobos VM, Aisner DL
    Ready or Not, Here I Come: Inflammatory Myofibroblastic Tumors With Kinase Alterations Revealed Through Molecular Hide and Seek.
    J Thorac Oncol. 2019;14:758-760.
    PubMed     Text format    
    
    
45. HANDRA-LUCA A
    Alveolar Septa Muscle: Subclinical Pulmonary Hypertension-Related Change or Malformation?
    J Thorac Oncol. 2019;14:e124-e125.
    PubMed     Text format    
    
    
46. CHIAPPETTA M, Petracca Ciavarella L, Margaritora S
    Can Pemetrexed Also Have a Potential Role Preoperatively in the Management of Advanced Thymic Epithelial Tumors?
    J Thorac Oncol. 2019;14:e89.
    PubMed     Text format    
    
    
47. MITSUDOMI T
    BRAF Fusion - Another Mechanism of Acquired Resistance to EGFR Tyrosine Kinase Inhibitors.
    J Thorac Oncol. 2019;14:764-765.
    PubMed     Text format    
    
    
48. GROEN HJM, Hiltermann TJN
    Air Pollution and Adenocarcinoma in Never-Smokers.
    J Thorac Oncol. 2019;14:761-763.
    PubMed     Text format    
    
    
49. ROTHSCHILD SI
    KRAS and Immune Checkpoint Inhibitors-Serendipity Raising Expectations.
    J Thorac Oncol. 2019;14:951-954.
    PubMed     Text format    
    
    

    
    Lung Cancer

50. YANG B, Lee H, Um SW, Kim K, et al
    Incidence of brain metastasis in lung adenocarcinoma at initial diagnosis on the basis of stage and genetic alterations.
    Lung Cancer. 2019;129:28-34.
    PubMed     Text format     Abstract available
    
    
51. BO L, Li C, Pan L, Wang H, et al
    Diagnosing a solitary pulmonary nodule using multiple bronchoscopic guided technologies: A prospective randomized study.
    Lung Cancer. 2019;129:48-54.
    PubMed     Text format     Abstract available
    
    
52. THAI AA, Stuart E, Te Marvelde L, Milne RL, et al
    Hospital lung surgery volume and patient outcomes.
    Lung Cancer. 2019;129:22-27.
    PubMed     Text format     Abstract available
    
    
53. ISHIDA H, Shimizu Y, Sakaguchi H, Nitanda H, et al
    Distinctive clinicopathological features of adenocarcinoma in situ and minimally invasive adenocarcinoma of the lung: A retrospective study.
    Lung Cancer. 2019;129:16-21.
    PubMed     Text format     Abstract available
    
    
54. LIU Y, Liu T, Li N, Wang T, et al
    Identification of a novel WNK1-ROS1 fusion in a lung adenocarcinoma sensitive to crizotinib.
    Lung Cancer. 2019;129:92-94.
    PubMed     Text format     Abstract available
    
    
55. WU L, Dell'Anno I, Lapidot M, Sekido Y, et al
    Progress of malignant mesothelioma research in basic science: A review of the 14th international conference of the international mesothelioma interest group (iMig2018).
    Lung Cancer. 2019;127:138-145.
    PubMed     Text format     Abstract available
    
    
56. ROCA E, Pozzari M, Vermi W, Tovazzi V, et al
    Outcome of EGFR-mutated adenocarcinoma NSCLC patients with changed phenotype to squamous cell carcinoma after tyrosine kinase inhibitors: A pooled analysis with an additional case.
    Lung Cancer. 2019;127:12-18.
    PubMed     Text format     Abstract available
    
    
57. HALMOS B, Tan EH, Soo RA, Cadranel J, et al
    Impact of afatinib dose modification on safety and effectiveness in patients with EGFR mutation-positive advanced NSCLC: Results from a global real-world study (RealGiDo).
    Lung Cancer. 2019;127:103-111.
    PubMed     Text format     Abstract available
    
    
58. MAUCLET C, Duplaquet F, Pirard L, Rondelet B, et al
    Complete tumor response of a locally advanced lung large-cell neuroendocrine carcinoma after palliative thoracic radiotherapy and immunotherapy with nivolumab.
    Lung Cancer. 2019;128:53-56.
    PubMed     Text format     Abstract available
    
    
59. ZHAO S, Li X, Zhao C, Jiang T, et al
    Loss of T790M mutation is associated with early progression to osimertinib in Chinese patients with advanced NSCLC who are harboring EGFR T790M.
    Lung Cancer. 2019;128:33-39.
    PubMed     Text format     Abstract available
    
    
60. TAKADA K, Kohashi K, Shimokawa M, Haro A, et al
    Co-expression of IDO1 and PD-L1 in lung squamous cell carcinoma: Potential targets of novel combination therapy.
    Lung Cancer. 2019;128:26-32.
    PubMed     Text format     Abstract available
    
    
61. TOFFART AC, Asfari S, Mc Leer A, Reymond E, et al
    Percutaneous CT-guided biopsy of lytic bone lesions in patients clinically suspected of lung cancer: Diagnostic performances for pathological diagnosis and molecular testing.
    Lung Cancer. 2019;140:93-98.
    PubMed     Text format     Abstract available
    
    
62. SMIT HJM, Aerts J, van den Heuvel M, Hiltermann TJN, et al
    Effects of checkpoint inhibitors in advanced non-small cell lung cancer at population level from the National Immunotherapy Registry.
    Lung Cancer. 2019;140:107-112.
    PubMed     Text format     Abstract available
    
    
63. GIAJ LEVRA M, Cotte FE, Corre R, Calvet C, et al
    Immunotherapy rechallenge after nivolumab treatment in advanced non-small cell lung cancer in the real-world setting: A national data base analysis.
    Lung Cancer. 2019;140:99-106.
    PubMed     Text format     Abstract available
    
    
64. MAZZASCHI G, Facchinetti F, Missale G, Canetti D, et al
    The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC.
    Lung Cancer. 2019;127:153-163.
    PubMed     Text format     Abstract available
    
    

    
    Lung Cancer (Auckl)

65. MIX M, Tanny S, Nsouli T, Alden R, et al
    Outcomes Following Stereotactic Body Radiotherapy with Intensity-Modulated Therapy versus Three-Dimensional Conformal Radiotherapy in Early Stage Non-Small Cell Lung Cancer.
    Lung Cancer (Auckl). 2019;10:151-159.
    PubMed     Text format     Abstract available
    
    

    
    Oncogene

66. LIU Y, Mao C, Wang M, Liu N, et al
    Cancer progression is mediated by proline catabolism in non-small cell lung cancer.
    Oncogene. 2020 Jan 7. pii: 10.1038/s41388-019-1151.
    PubMed     Text format     Abstract available
    
    

    
    Oncol Rep

67. XIONG J, Xing S, Dong Z, Niu L, et al
    STK31 regulates the proliferation and cell cycle of lung cancer cells via the Wnt/betacatenin pathway and feedback regulation by cmyc.
    Oncol Rep. 2019 Dec 19. doi: 10.3892/or.2019.7441.
    PubMed     Text format     Abstract available
    
    
68. HUANG W, Wu Y, Cheng D, He Z, et al
    Mechanism of epithelialmesenchymal transition inhibited by miR203 in nonsmall cell lung cancer.
    Oncol Rep. 2019 Dec 13. doi: 10.3892/or.2019.7433.
    PubMed     Text format     Abstract available
    
    
69. HU Z, Zhao P, Xu H
    Hyperoside exhibits anticancer activity in nonsmall cell lung cancer cells with T790M mutations by upregulating FoxO1 via CCAT1.
    Oncol Rep. 2019 Dec 18. doi: 10.3892/or.2019.7440.
    PubMed     Text format     Abstract available
    
    
70. KIM DS, Lee WK, Park JY
    Association of FOSB exon 4 unmethylation with poor prognosis in patients with latestage nonsmall cell lung cancer.
    Oncol Rep. 2019 Dec 13. doi: 10.3892/or.2019.7431.
    PubMed     Text format     Abstract available
    
    
71. TANG X, Li Y, Liu L, Guo R, et al
    Sirtuin 3 induces apoptosis and necroptosis by regulating mutant p53 expression in smallcell lung cancer.
    Oncol Rep. 2019 Dec 17. doi: 10.3892/or.2019.7439.
    PubMed     Text format     Abstract available
    
    

    
    PLoS One

72. GU Y, Cheng Y, Song Y, Zhang Z, et al
    Retraction: MicroRNA-493 Suppresses Tumor Growth, Invasion and Metastasis of Lung cancer by Regulating E2F1.
    PLoS One. 2019;14:e0227503.
    PubMed     Text format    
    
    
73. MATSUBARA T, Toyokawa G, Takada K, Kinoshita F, et al
    The association and prognostic impact of enhancer of zeste homologue 2 expression and epithelial-mesenchymal transition in resected lung adenocarcinoma.
    PLoS One. 2019;14:e0215103.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: